Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 20040391 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Amgen | INDUSTRY |
| Barr Laboratories | INDUSTRY |
| Pfizer | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanercept or reserve this treatment for patients who do not appropriately respond to methotrexate alone and 2) to determine which combination of methotrexate therapy is better
The ultimate goal of RA is to eliminate symptoms, restoring the patient to normal physical, social, emotional, and vocational function, and preserving the structure and integrity of joints. While disease modifying anti-rheumatic drugs (DMARDs) have long been the cornerstone of RA therapy, the limitations of DMARDs have become increasingly apparent and investigators continue to gain insight into the pathogenesis of this disease. Recent evidence suggests that treatment earlier in the disease process with more aggressive approaches results in superior long-term outcomes compared to less intensive treatment regimens. Specifically, there is growing interest in the possibility that early "aggressive" treatment with combinations of DMARDs as initial treatment in efforts to potentially reduce the proportion of patients that advance to severe disability.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Active Comparator | methotrexate (MTX) + etanercept |
|
| 2 | Active Comparator | methotrexate (MTX) + sulfasalazine (SSZ)/hydroxychloroquine (HCQ) |
|
| 3 | Active Comparator | methotrexate (MTX) or MTX + Etanercept |
|
| 4 | Active Comparator | methotrexate (MTX) or MTX + sulfasalazine (SSZ)/hydroxychloroquine (HCQ) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| methotrexate | Drug | varies |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Disease Activity Score Erythrocyte Sedimentation Rate(DAS28-ESR) | Outcome measured was the observed-group analysis of the DAS28-ESR between weeks 48 and 102. DAS28 is a calculated scale using a formula that includes the number of tender joints and swollen joints (28 joints maximum). The following is the calculation: DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(swollen28) + 0.70 * ln(ESR) + 0.014 * GH. The ESR is the rate at which red blood cells sediment in a period of one hour. The total range for the DAS28ESR goes from 0.0 to 9.2; this indicates the current activity of the rheumatoid arthritis of a subject. A DAS28 above 5.1 means high disease activity whereas a DAS28 below 3.2 indicates low disease activity. | Change of the Mean of DAS28-ESR between weeks 48 - 102. |
| Measure | Description | Time Frame |
|---|---|---|
| Radiographic Disease Progression Between Baseline and Week 102 as Assessed by Van Der Heijde Modified Sharp Scores. | Changes in disease progression between treatment groups will be described by the mean score at two years as assessed after adjustment for the baseline radiographic score. Radiographs were observed of hands, wrists, and feet. The range of scores available for the modified Sharp Score is 0 to 448. The erosion score per joint of the hands can range from 0 to 5. The maximal erosion score for each hand is thus 80, considering the 16 areas for erosions per hand. Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4 with a max score of 60. The erosion score per joint can range from 0 to 10, with each side of the joint independently scored from 0 to 5. The maximal erosion score per foot is thus 60. The joint space narrowing and joint (sub)luxation are combined in a single score with a range of 0 to 4. The maximal narrowing/(sub)luxation score per foot is thus 24. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jeffrey Curtis, MD | University of Alabama at Birmingham | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 22508468 | Result | Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL Jr, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS; TEAR Investigators. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012 Sep;64(9):2824-35. doi: 10.1002/art.34498. | |
| 27483410 |
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
This study had a screening period of 1-3 days, Patients were excluded for various reasons, including, laboratory exclusions, Positive TB test, and Cataract/visual defect.
Recruitment began in May 2004 and concluded in January 2007.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | MTX + Active Etanercept | Methotrexate (MTX)5mg -20mg/qw by mouth(within 12 weeks of entry in study) + etanercept 50mg/qw by injection |
| FG001 | MTX+ Active SSZ +HCQ | methotrexate (MTX)20mg/qw by mouth(within 12 weeks of entry in study) + sulfasalazine (SSZ) 500mg qd - 1000mg 2qd by mouth /hydroxychloroquine (HCQ)200mg 2qd by mouth |
| FG002 | MTX + Placebo Entaneracept | Methotrexate (MTX)5mg -20mg/qw by mouth(within 12 weeks of entry in study) + Etanercept(Placebo) 50mg/qw by injection |
| FG003 | MTX + Placebo SSZ + HCQ(ST) | Methotrexate (MTX)5mg -20mg/qw by mouth(within 12 weeks of entry in study) + sulfasalazine (SSZ) 500mg qd - 1000mg 2qd by mouth /hydroxychloroquine (HCQ)200mg 2qd by mouth |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | MTX + Active Etanercept | Methotrexate (MTX) + etanercept |
| BG001 | MTX+ Active SSZ +HCQ | methotrexate (MTX) + sulfasalazine (SSZ)/hydroxychloroquine (HCQ) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Disease Activity Score Erythrocyte Sedimentation Rate(DAS28-ESR) | Outcome measured was the observed-group analysis of the DAS28-ESR between weeks 48 and 102. DAS28 is a calculated scale using a formula that includes the number of tender joints and swollen joints (28 joints maximum). The following is the calculation: DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(swollen28) + 0.70 * ln(ESR) + 0.014 * GH. The ESR is the rate at which red blood cells sediment in a period of one hour. The total range for the DAS28ESR goes from 0.0 to 9.2; this indicates the current activity of the rheumatoid arthritis of a subject. A DAS28 above 5.1 means high disease activity whereas a DAS28 below 3.2 indicates low disease activity. | The participants that were randomized into this clinical trial and completed the study to year 2, represent the number for analysis. | Posted | Mean | Standard Deviation | Scores on a scale | Change of the Mean of DAS28-ESR between weeks 48 - 102. |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | MTX + Active Etanercept | Methotrexate (MTX) + etanercept |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Jeffrey R. Curtis, | University of Alabama at Birmingham | 205-934-7733 | jcurtis@uab.edu |
Not provided
| ID | Term |
|---|---|
| D001172 | Arthritis, Rheumatoid |
| D018771 | Arthralgia |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008727 | Methotrexate |
| D012460 | Sulfasalazine |
| D006886 | Hydroxychloroquine |
| D000068800 | Etanercept |
| ID | Term |
|---|---|
| D000630 | Aminopterin |
| D011622 | Pterins |
| D011621 | Pteridines |
| D006574 | Heterocyclic Compounds, 2-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| sulfasalazine |
| Drug |
varies |
|
| hydroxychloroquine | Drug | varies |
|
| etanercept | Drug | varies |
|
| Year 2, Week 102 |
| Derived |
| Charles-Schoeman C, Yin Lee Y, Shahbazian A, Wang X, Elashoff D, Curtis JR, Navarro-Millan I, Yang S, Chen L, Cofield SS, Moreland LW, Paulus H, O'Dell J, Bathon J, Louis Bridges S Jr, Reddy ST. Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial. Arthritis Rheumatol. 2017 Jan;69(1):46-57. doi: 10.1002/art.39833. |
| 27188329 | Derived | Hwang YG, Balasubramani GK, Metes ID, Levesque MC, Bridges SL Jr, Moreland LW. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value as a disease activity biomarker. Arthritis Res Ther. 2016 May 17;18(1):108. doi: 10.1186/s13075-016-1009-y. |
| 26606398 | Derived | Charles-Schoeman C, Wang X, Lee YY, Shahbazian A, Navarro-Millan I, Yang S, Chen L, Cofield SS, Moreland LW, O'Dell J, Bathon JM, Paulus H, Bridges SL Jr, Curtis JR. Association of Triple Therapy With Improvement in Cholesterol Profiles Over Two-Year Followup in the Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheumatol. 2016 Mar;68(3):577-86. doi: 10.1002/art.39502. |
| 22730343 | Derived | Maska LB, Sayles HR, O'Dell JR, Curtis JR, Bridges SL Jr, Moreland LW, Cofield SS, Mikuls TR. Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 Dec;64(12):1804-10. doi: 10.1002/acr.21758. |
| Lost to Follow-up |
|
| Physician Decision |
|
| Death |
|
| non medical reason |
|
| Adverse Event |
|
| Serious Adverse Event |
|
| BG002 | MTX + Placebo Entaneracept | methotrexate (MTX) or MTX + Etanercept |
| BG003 | MTX + Placebo SSZ + HCQ(ST) | methotrexate (MTX) or MTX + sulfasalazine (SSZ)/hydroxychloroquine (HCQ) |
| BG004 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
Methotrexate (MTX) + etanercept |
| OG001 | MTX+ Immediate SSZ +HCQ | methotrexate (MTX) + sulfasalazine (SSZ)/hydroxychloroquine (HCQ) |
| OG002 | MTX + Step-up Etanercept | methotrexate (MTX) or MTX + Etanercept |
| OG003 | MTX + Step-up SSZ + HCQ(ST) | methotrexate (MTX) or MTX + sulfasalazine (SSZ)/hydroxychloroquine (HCQ) |
|
|
| Secondary | Radiographic Disease Progression Between Baseline and Week 102 as Assessed by Van Der Heijde Modified Sharp Scores. | Changes in disease progression between treatment groups will be described by the mean score at two years as assessed after adjustment for the baseline radiographic score. Radiographs were observed of hands, wrists, and feet. The range of scores available for the modified Sharp Score is 0 to 448. The erosion score per joint of the hands can range from 0 to 5. The maximal erosion score for each hand is thus 80, considering the 16 areas for erosions per hand. Joint space narrowing and joint subluxation or luxation are combined in a single score with a range of 0 to 4 with a max score of 60. The erosion score per joint can range from 0 to 10, with each side of the joint independently scored from 0 to 5. The maximal erosion score per foot is thus 60. The joint space narrowing and joint (sub)luxation are combined in a single score with a range of 0 to 4. The maximal narrowing/(sub)luxation score per foot is thus 24. | The participants that were randomized into this clinical trial and completed the study to year 2, represent the number for analysis. | Posted | Mean | Standard Deviation | Scores on a scale | Year 2, Week 102 |
|
|
|
| 35 |
| 244 |
| 184 |
| 244 |
| EG001 | MTX+ Active SSZ +HCQ | methotrexate (MTX) + sulfasalazine (SSZ)/hydroxychloroquine (HCQ) | 18 | 132 | 99 | 132 |
| EG002 | MTX + Placebo Entaneracept | methotrexate (MTX) or MTX + Etanercept | 32 | 255 | 180 | 255 |
| EG003 | MTX + Placebo SSZ + HCQ(ST) | methotrexate (MTX) or MTX + sulfasalazine (SSZ)/hydroxychloroquine (HCQ) | 16 | 124 | 89 | 124 |
| Acute Arterial Thromboembolism | Blood and lymphatic system disorders | Systematic Assessment |
|
| Dehydration | Blood and lymphatic system disorders | Systematic Assessment |
|
| Arterial Blockage | Cardiac disorders | Systematic Assessment |
|
| Congestive Heart Failure | Cardiac disorders | Systematic Assessment |
|
| Chronic obstructive pulmonary disease | Cardiac disorders | Systematic Assessment |
|
| Chest Pain | Cardiac disorders | Systematic Assessment |
|
| Death | Cardiac disorders | Systematic Assessment |
|
| Hypertension | Cardiac disorders | Systematic Assessment |
|
| Left Anterior Descending Stenosis | Cardiac disorders | Systematic Assessment |
|
| Myocardial Infarction | Cardiac disorders | Systematic Assessment |
|
| Other Infection | Eye disorders | Systematic Assessment |
|
| Bowel Obstruction | Gastrointestinal disorders | Systematic Assessment |
|
| Dehydration | Gastrointestinal disorders | Systematic Assessment |
|
| Dilated Bowel | Gastrointestinal disorders | Systematic Assessment |
|
| Nausea / Vomiting | Gastrointestinal disorders | Systematic Assessment |
|
| Other Infection | Gastrointestinal disorders | Systematic Assessment |
|
| Perforated Bowel | Gastrointestinal disorders | Systematic Assessment |
|
| Dehydration | General disorders | Systematic Assessment |
|
| Syncopal Episode | General disorders | Systematic Assessment |
|
| Angioedema | General disorders | Systematic Assessment |
|
| Bronchitis | Infections and infestations | Systematic Assessment |
|
| Cellulitis | Infections and infestations | Systematic Assessment |
|
| Herpes Zoster | Infections and infestations | Systematic Assessment |
|
| Malaria | Infections and infestations | Systematic Assessment |
|
| Other Infection | Infections and infestations | Systematic Assessment |
|
| Pneumonia | Infections and infestations | Systematic Assessment |
|
| Fracture | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Injury | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Elevated LFTs | Investigations | Systematic Assessment |
|
| Low Hemoglobin | Investigations | Systematic Assessment |
|
| Renal Failure | Investigations | Systematic Assessment |
|
| Diabetes | Metabolism and nutrition disorders | Systematic Assessment |
|
| Fracture | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Joint Pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| Cerebellar Infarcation w/ Hydrocephalus | Nervous system disorders | Systematic Assessment |
|
| Chronic Intracranial Hemorrhage | Nervous system disorders | Systematic Assessment |
|
| Headaches | Nervous system disorders | Systematic Assessment |
|
| Neuropathy | Nervous system disorders | Systematic Assessment |
|
| Seizure | Nervous system disorders | Systematic Assessment |
|
| Miscarriage | Pregnancy, puerperium and perinatal conditions | Systematic Assessment |
|
| Pregnancy | Pregnancy, puerperium and perinatal conditions | Systematic Assessment |
|
| Confusion | Psychiatric disorders | Systematic Assessment |
|
| Depression | Psychiatric disorders | Systematic Assessment |
|
| Psychosis | Psychiatric disorders | Systematic Assessment |
|
| Suicidal Ideation | Psychiatric disorders | Systematic Assessment |
|
| Surgical Procedure | Reproductive system and breast disorders | Systematic Assessment |
|
| COPD | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Cancer | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Chest Pain | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Death | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Other Infection | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Pneumocystis Carini | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Pneumonia | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Pulmonary Fibrosis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Shortness of Breath | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Cerebral Vascular Accident | Surgical and medical procedures | Systematic Assessment |
|
| Fracture | Surgical and medical procedures | Systematic Assessment |
|
| Joint Replacement | Surgical and medical procedures | Systematic Assessment |
|
| Joint Surgery | Surgical and medical procedures | Systematic Assessment |
|
| Other Infection | Surgical and medical procedures | Systematic Assessment |
|
| Perforated Bowel | Surgical and medical procedures | Systematic Assessment |
|
| Surgical Procedure | Surgical and medical procedures | Systematic Assessment |
|
| Pulmonary Edema | Vascular disorders | Systematic Assessment |
|
| Swelling | Vascular disorders | Systematic Assessment |
|
| Pulmonary embolus | Vascular disorders | Systematic Assessment |
|
| Transient Ischemic Attack | Vascular disorders | Systematic Assessment |
|
| Edema | Blood and lymphatic system disorders | Systematic Assessment |
|
| Nose Bleed | Blood and lymphatic system disorders | Systematic Assessment |
|
| Purpura | Blood and lymphatic system disorders | Systematic Assessment |
|
| Arrhythmia | Cardiac disorders | Systematic Assessment |
|
| Chest Pain | Cardiac disorders | Systematic Assessment |
|
| Congestive heart failure | Cardiac disorders | Systematic Assessment |
|
| Hypertension | Cardiac disorders | Systematic Assessment |
|
| Hypotension | Cardiac disorders | Systematic Assessment |
|
| PALPITATIONS | Cardiac disorders | Systematic Assessment |
|
| SHORTNESS OF BREATH | Cardiac disorders | Systematic Assessment |
|
| VENTRICULAR HYPERTROPHY | Cardiac disorders | Systematic Assessment |
|
| EAR CONGESTION/FULLNESS | Ear and labyrinth disorders | Systematic Assessment |
|
| EARACHE/ INFECTION | Ear and labyrinth disorders | Systematic Assessment |
|
| HEARING LOSS | Ear and labyrinth disorders | Systematic Assessment |
|
| TINNITUS | Ear and labyrinth disorders | Systematic Assessment |
|
| DIABETES | Endocrine disorders | Systematic Assessment |
|
| HYPO/HYPERTHYROIDISM | Endocrine disorders | Systematic Assessment |
|
| THYROID ENLARGEMENT/NODULES | Endocrine disorders | Systematic Assessment |
|
| CATARACT | Eye disorders | Systematic Assessment |
|
| DECREASED VISION | Eye disorders | Systematic Assessment |
|
| DRY EYES | Eye disorders | Systematic Assessment |
|
| EYE IRRITATION | Eye disorders | Systematic Assessment |
|
| GLAUCOMA | Eye disorders | Systematic Assessment |
|
| KERATITIS | Eye disorders | Systematic Assessment |
|
| MELANOSIS | Eye disorders | Systematic Assessment |
|
| OTHER SURGERY/PROCEDURE | Eye disorders | Systematic Assessment |
|
| PARACENTRAL DEPRESSIONS | Eye disorders | Systematic Assessment |
|
| PHOTOPHOBIA | Eye disorders | Systematic Assessment |
|
| SJORGRENS SYNDROME | Eye disorders | Systematic Assessment |
|
| SUBCONJUNCTIVAL HEMORRHAGE | Eye disorders | Systematic Assessment |
|
| XANTHELASMA | Eye disorders | Systematic Assessment |
|
| ABDOMINAL CRAMPS/PAIN | Gastrointestinal disorders | Systematic Assessment |
|
| ALTERED TASTE | Gastrointestinal disorders | Systematic Assessment |
|
| BLACK STOOLS | Gastrointestinal disorders | Systematic Assessment |
|
| CONSTIPATION | Gastrointestinal disorders | Systematic Assessment |
|
| DIARRHEA/LOOSE STOOLS | Gastrointestinal disorders | Systematic Assessment |
|
| DIVERTICULITIS | Gastrointestinal disorders | Systematic Assessment |
|
| DYSPHAGIA | Gastrointestinal disorders | Systematic Assessment |
|
| FLATULENCE | Gastrointestinal disorders | Systematic Assessment |
|
| GERD | Gastrointestinal disorders | Systematic Assessment |
|
| GI FLU | Gastrointestinal disorders | Systematic Assessment |
|
| GI ULCER | Gastrointestinal disorders | Systematic Assessment |
|
| HEMORRHOIDS | Gastrointestinal disorders | Systematic Assessment |
|
| INFLAMMATORY BOWEL DISEASE | Gastrointestinal disorders | Systematic Assessment |
|
| NAUSEA/VOMITING | Gastrointestinal disorders | Systematic Assessment |
|
| OCCLUDED/SWOLLEN SALIVARY GLAND | Gastrointestinal disorders | Systematic Assessment |
|
| ORAL ULCERS | Gastrointestinal disorders | Systematic Assessment |
|
| OTHER INFECTION | Gastrointestinal disorders | Systematic Assessment |
|
| RECTAL BLEEDING | Gastrointestinal disorders | Systematic Assessment |
|
| ALOPECIA | General disorders | Systematic Assessment |
|
| ALTERED TASTE | General disorders | Systematic Assessment |
|
| BURNING SENSATION | General disorders | Systematic Assessment |
|
| CHILLS/SWEATS | General disorders | Systematic Assessment |
|
| DENTAL PAIN/INFECTION/ABSCESS | General disorders | Systematic Assessment |
|
| DRY MOUTH | General disorders | Systematic Assessment |
|
| FATIGUE | General disorders | Systematic Assessment |
|
| HOARSENESS OF VOICE | General disorders | Systematic Assessment |
|
| HOT FLASHES | General disorders | Systematic Assessment |
|
| INJECTION SITE REACTION | General disorders | Systematic Assessment |
|
| INJURY | General disorders | Systematic Assessment |
|
| INSOMINA | General disorders | Systematic Assessment |
|
| INSOMNIA | General disorders | Systematic Assessment |
|
| Other | Gastrointestinal disorders | Systematic Assessment |
|
| SLEEP APNEA | General disorders | Systematic Assessment |
|
| SORE TONGUE | General disorders | Systematic Assessment |
|
| SYNCOPY | General disorders | Systematic Assessment |
|
| TONGUE FISSURES | General disorders | Systematic Assessment |
|
| VOICE HOARSENESS | General disorders | Systematic Assessment |
|
| CHOLECYSTITIS/CHOLELITHIASIS | Hepatobiliary disorders | Systematic Assessment |
|
| FATTY LIVER | Hepatobiliary disorders | Systematic Assessment |
|
| HEPATOMEGALY | Hepatobiliary disorders | Systematic Assessment |
|
| ALLERGIC REACTION | Immune system disorders | Systematic Assessment |
|
| SEASONAL ALLERGY | Immune system disorders | Systematic Assessment |
|
| CANDIDIASIS | Infections and infestations | Systematic Assessment |
|
| COMMON COLD | Infections and infestations | Systematic Assessment |
|
| COUGH | Infections and infestations | Systematic Assessment |
|
| DENTAL PAIN/INFECTION/ABSCESS | Infections and infestations | Systematic Assessment |
|
| DERMATALOGIC ERUPTION | Infections and infestations | Systematic Assessment |
|
| EARACHE/ INFECTION | Infections and infestations | Systematic Assessment |
|
| EYE INFECTION | Infections and infestations | Systematic Assessment |
|
| Fever | Infections and infestations | Systematic Assessment |
|
| FLU /FLU LIKE SYMPTOMS | Infections and infestations | Systematic Assessment |
|
| HERPES | Infections and infestations | Systematic Assessment |
|
| INFECTED FINGER | Infections and infestations | Systematic Assessment |
|
| INFECTED TOENAIL | Infections and infestations | Systematic Assessment |
|
| LYMPHADENOPATHY/LYMPHADENITIS | Infections and infestations | Systematic Assessment |
|
| OTHER INFECTION | Infections and infestations | Systematic Assessment |
|
| PHARYNGITIS | Infections and infestations | Systematic Assessment |
|
| Pneumonia | Infections and infestations | Systematic Assessment |
|
| PROSTATE INFECTION/ENLARGEMENT | Infections and infestations | Systematic Assessment |
|
| SINUS INFECTION | Infections and infestations | Systematic Assessment |
|
| SORE THROAT | Infections and infestations | Systematic Assessment |
|
| STREP THROAT | Infections and infestations | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | Systematic Assessment |
|
| Urinary Tract Infection | Infections and infestations | Systematic Assessment |
|
| Vaginal/Pelvic Infection | Infections and infestations | Systematic Assessment |
|
| Weight gain | Infections and infestations | Systematic Assessment |
|
| Burn | Injury, poisoning and procedural complications | Systematic Assessment |
|
| DERMATALOGIC ERUPTION | Injury, poisoning and procedural complications | Systematic Assessment |
|
| EXTREMITY SPRAIN/CRAMPS | Injury, poisoning and procedural complications | Systematic Assessment |
|
| FRACTURE | Injury, poisoning and procedural complications | Systematic Assessment |
|
| INJURY | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Joint Pain | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Other | Injury, poisoning and procedural complications | Systematic Assessment |
|
| anemia | Investigations | Systematic Assessment |
|
| ELEVATED CK AND ALDOLASE | Investigations | Systematic Assessment |
|
| ELEVATED CREATININE | Investigations | Systematic Assessment |
|
| ELEVATED LIVER ENZYMES | Investigations | Systematic Assessment |
|
| HYPERCHOLESTEROLEMIA | Investigations | Systematic Assessment |
|
| HYPERGLYCEMIA | Investigations | Systematic Assessment |
|
| HYPERKALEMIA | Investigations | Systematic Assessment |
|
| INCREASED ESR | Investigations | Systematic Assessment |
|
| LABORATORY ERROR | Investigations | Systematic Assessment |
|
| LEUKOCYTOSIS/LEUKOPENIA | Investigations | Systematic Assessment |
|
| OTHER SURGERY/PROCEDURE | Investigations | Systematic Assessment |
|
| THROMBOCYTOSIS/THROMBOCYTOPENIA | Investigations | Systematic Assessment |
|
| VITAMIN B-12 DEFICIENCY | Metabolism and nutrition disorders | Systematic Assessment |
|
| CHEST PAIN | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| EXTREMITY SPRAIN/CRAMPS | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| FIBROMYALGIA | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| FRACTURE | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| GOUT | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| HEALED FRACTURE | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| HERNIA | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Joint Pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Joint Surgery/Procedure | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Mixed Connective Tissue Disease | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| DERMATALOGIC ERUPTION | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| LUMP/NODULE | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| LUNG CANCER | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| RENAL CARCINOMA | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| SKIN CANCER | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| SUBUNGUAL NEVUS | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| THYROID ENLARGEMENT/NODULES | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
|
| CHARCOT MARIE SYNDROME | Nervous system disorders | Systematic Assessment |
|
| DIZZINESS | Nervous system disorders | Systematic Assessment |
|
| FACIAL DROOP | Nervous system disorders | Systematic Assessment |
|
| HEADACHE | Nervous system disorders | Systematic Assessment |
|
| MEMORY LOSS/CONFUSION | Nervous system disorders | Systematic Assessment |
|
| NEUROMA | Nervous system disorders | Systematic Assessment |
|
| NEUROPATHY | Nervous system disorders | Systematic Assessment |
|
| NUMBNESS, DROOPING | Nervous system disorders | Systematic Assessment |
|
| SEIZURE | Nervous system disorders | Systematic Assessment |
|
| SYNCOPY | Nervous system disorders | Systematic Assessment |
|
| TREMORS | Nervous system disorders | Systematic Assessment |
|
| ANXIETY/NERVOUSNESS/IRRITABILITY | Psychiatric disorders | Systematic Assessment |
|
| BIPOLAR DISORDER | Psychiatric disorders | Systematic Assessment |
|
| DEPRESSION | Psychiatric disorders | Systematic Assessment |
|
| METHADONE WITHDRAWAL | Psychiatric disorders | Systematic Assessment |
|
| DYSURIA | Renal and urinary disorders | Systematic Assessment |
|
| HEMATURIA | Renal and urinary disorders | Systematic Assessment |
|
| NOCTURIA | Renal and urinary disorders | Systematic Assessment |
|
| RENAL CALCULI | Renal and urinary disorders | Systematic Assessment |
|
| URINARY INCONTINENCE/FREQUENCY/URGENCY | Renal and urinary disorders | Systematic Assessment |
|
| ABNORMAL MENSES | Reproductive system and breast disorders | Systematic Assessment |
|
| ATYPICAL PAP TEST | Reproductive system and breast disorders | Systematic Assessment |
|
| PROLAPSED UTERUS | Reproductive system and breast disorders | Systematic Assessment |
|
| PROSTATE INFECTION/ENLARGEMENT | Reproductive system and breast disorders | Systematic Assessment |
|
| VAGINAL DISCHARGE/BLEEDING | Reproductive system and breast disorders | Systematic Assessment |
|
| VAGINAL DRYNESS | Reproductive system and breast disorders | Systematic Assessment |
|
| ASTHMA/COPD | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| CHEST PAIN | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| NOSE BLEED | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| PLEURAL EFFUSION | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| SHORTNESS OF BREATH | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| TRACHEAL STENOSIS | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| BRITTLE FINGERNAILS | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| CHILLS/SWEATS | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| DELAYED WOUND HEALING | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| DERMATALOGIC ERUPTION | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| INJURY | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| MELASMA | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| NASAL IRRITATION/EROSION | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| ORAL ULCERS | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| OTHER | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| OTHER INFECTION | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| PEELING SKIN | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| PETECHIA | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| PLANTAR FASCITIS | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| POOR WOUND HEALING | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| SUPRACLAVICULAR FAT PADS | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| CATARACT | Surgical and medical procedures | Systematic Assessment |
|
| DENTAL PAIN/INFECTION/ABSCESS | Surgical and medical procedures | Systematic Assessment |
|
| DERMATALOGIC ERUPTION | Surgical and medical procedures | Systematic Assessment |
|
| FRACTURE | Surgical and medical procedures | Systematic Assessment |
|
| INJURY | Surgical and medical procedures | Systematic Assessment |
|
| JOINT SURGERY/PROCEDURE | Surgical and medical procedures | Systematic Assessment |
|
| OTHER SURGERY/PROCEDURE | Surgical and medical procedures | Systematic Assessment |
|
| CLAUDICATION | Vascular disorders | Systematic Assessment |
|
| DEEP VEIN THROMBOSIS | Vascular disorders | Systematic Assessment |
|
| NOSE BLEED | Vascular disorders | Systematic Assessment |
|
| PERIPHERAL VASCULAR DISEASE | Vascular disorders | Systematic Assessment |
|
| THROMBOPHLEBITIS | Vascular disorders | Systematic Assessment |
|
| VARICOSE VEIN | Vascular disorders | Systematic Assessment |
|
Not provided
| D003240 |
| Connective Tissue Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000072471 |
| Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D002738 | Chloroquine |
| D000634 | Aminoquinolines |
| D011804 | Quinolines |
| D007141 | Immunoglobulin Fc Fragments |
| D007128 | Immunoglobulin Fragments |
| D010446 | Peptide Fragments |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D007127 | Immunoglobulin Constant Regions |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D018124 | Receptors, Tumor Necrosis Factor |
| D018121 | Receptors, Cytokine |
| D011971 | Receptors, Immunologic |
| D011956 | Receptors, Cell Surface |
| D008565 | Membrane Proteins |